- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02521974
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children (M2-ABMG)
August 1, 2020 updated by: Fidec Corporation
A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants
Sabin 2 will be withdrawn from routine use globally from April 2016 as per the SAGE recommendations at the time of writing this protocol.
After this cessation of OPV2, stockpiles of mOPV2 will be maintained for potential use if necessary in response to a future outbreak.
However, there will be a risk of cVDPV2 from Sabin 2 in settings of low population immunity.
Research is ongoing to develop vaccines that are genetically more stable than the currently available Sabin 2-containing OPVs.
To generate data on immunogenicity, safety, and genetic stability on the Sabin 2 vaccine (mOPV2) and as a future comparator for new polio vaccine research after the global switch from tOPV to bOPV, this study with mOPV2 is performed to evaluate safety, immunogenicity (humoral and intestinal) and genetic stability endpoints of mOPV2 in children aged 1 to 5 years and in infants approximately 18 weeks of aged vaccinated with bOPV-/IPV for better understanding of the stockpile use of this vaccine, and for comparison with any potential new polio vaccine with a type 2 component in the future.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- PRIMARY OBJECTIVE The primary objectives of the study are to assess the safety (serious adverse events [SAEs] and severe adverse events [AEs] grade 3 according to CTCAE 4.03 and immunogenicity (seroprotection rate) of a single dose of SABIN mOPV2 in healthy children aged 1 to 5 years old, and in infants at approximately 18 weeks of age after having been vaccinated with 3 doses of bOPV and 1 dose of IPV .
SECONDARY OBJECTIVES
Secondary objectives are to assess:
- The safety (mild and moderate solicited and unsolicited AEs, Important Medical Events [IMEs], and laboratory deviation assessments) of one or two doses of SABIN mOPV2 in healthy children aged 1 to 5 years, and of 2 doses of SABIN mOPV2 in infants at approximately 18 and 22 weeks of age after having been vaccinated with 3 doses of bOPV and 1 dose of IPV.
- The immunogenicity (seroconversion rate, median and geometric mean antibody titers) of one or two doses of SABIN mOPV2 in healthy children aged 1 to 5 years old, and of two doses of SABIN mOPV2 in infants at approximately 18 22 weeks of age after having been vaccinated with 3 doses of bOPV and 1 dose of IPV.
- EXPLORATORY OBJECTIVES
Exploratory objectives are:
- To investigate viral shedding following the SABIN mOPV2 administration.
- Exploratory objectives may also include assessment of the genetic sequence heterogeneity and potential for neurovirulence (as measured in animal model(s)) of shed virus.
- To investigate viral shedding and neurovirulence of shed virus;
- To evaluate genetic reversion at position nt481 (primarily) and other secondary sites (e.g., nt2908).
- To investigate the priming responses of bOPV for mOPV2. (group 2 only) and the duration of induction of anti-polio type 2 neutralizing antibodies .
Study Type
Interventional
Enrollment (Actual)
164
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 5 years (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children aged 1 to 5 years previously vaccinated with three or four doses of IPV (Group 1) or unvaccinated infants aged 6 weeks (-7 to +14 days) (Groups 2 and 3).
- For Groups 2 and 3 (enrolled at 6 weeks of age) infants must have been vaccinated with 3 doses of bOPV and one dose of IPV prior to administration of the study vaccine, and the last Polio vaccine must have been administered at least 4 weeks prior to the study vaccine.
- Healthy without obvious medical conditions that preclude the subject to be in the study as established by the medical history and physical examination.
- Written informed consent obtained from 1 or 2 parent(s) or legal guardian(s) as per country regulations.
Exclusion Criteria:
- For Group 1: polio vaccines within the 3 months prior to the administration of the study vaccine (number of previous polio vaccine doses to be documented). For Groups 2 and 3: polio vaccines prior to administration of the study vaccine other than 3 doses of bOPV and 1 dose of IPV .
- Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus (HIV) infection.
- Family history of congenital or hereditary immunodeficiency.
- Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).
- Known allergy to any component of the study vaccines or to any antibiotics.
- Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections (of IPV).
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all in/exclusion criteria are met.).
- Member of the subject's household (living in the same house or apartment unit) has received OPV in the last 3 months.
- Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SABIN monovalent OPV2 vaccine
SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
|
SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Experiencing SAEs, Severe AEs (Grade 3), and/or IMEs
Time Frame: 6 months
|
Number of subjects experiencing SAEs, severe AEs (grade 3), and IMEs considered consistent with a causal association to study vaccine throughout the study period in all groups.
|
6 months
|
Seroprotection Rate of Type 2 Polio Neutralizing Antibodies.
Time Frame: 28 days
|
Measured at Day 28 following a single dose of Sabin mOPV2 in both infant groups (Groups 2+3). Seroprotection is defined as type 2-specific antibody titers ≥1:8 and seroprotection rate as the percentage of seroprotected subjects per group. |
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Xavier M Saez-Llorens, MD, Hospital del Niño de Panama
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2015
Primary Completion (ACTUAL)
July 1, 2016
Study Completion (ACTUAL)
September 29, 2016
Study Registration Dates
First Submitted
July 31, 2015
First Submitted That Met QC Criteria
August 12, 2015
First Posted (ESTIMATE)
August 13, 2015
Study Record Updates
Last Update Posted (ACTUAL)
August 14, 2020
Last Update Submitted That Met QC Criteria
August 1, 2020
Last Verified
July 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- M2-ABMG
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Event Following Immunisation
-
Duke UniversityBoston Medical Center; Centers for Disease Control and Prevention; Children's...CompletedSafety | Birth Outcomes | Adverse Event Following ImmunisationUnited States
-
The Ottawa HospitalCompletedMobile Apps | Immunization | Adverse Event Following ImmunisationCanada
-
Centers for Disease Control and Prevention, ChinaBeijing Tiantan Biological Products Co., Ltd.CompletedMeasles | Rubella | Mumps | Adverse Event Following ImmunisationChina
-
Xuanwu Hospital, BeijingUnknown
-
Nantes University HospitalUniversité de NantesNot yet recruiting
-
Université du Québec à Trois-RivièresCompleted
-
Hospices Civils de LyonUnknown
-
Universidad Miguel Hernandez de ElcheFundación para el Fomento de la Investigación Sanitaria y Biomédica de la...Active, not recruiting
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruitingImmune-related Adverse EventTaiwan
-
Lucie HeinzerlingRecruitingImmune-related Adverse EventGermany
Clinical Trials on SABIN monovalent OPV2
-
PATHBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; The Emmes Company, LLC and other collaboratorsCompleted
-
China National Biotec Group Company LimitedPeking University; Hubei Provincial Center for Disease Control and Prevention; Shaanxi Provincial Center for Disease Control and Prevention and other collaboratorsCompletedTo Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPVVaccination | Reaction - VaccineChina
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company LimitedCompleted
-
Pierre Van DammeBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PA... and other collaboratorsCompleted
-
Pierre Van DammeBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PA... and other collaboratorsCompleted
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaboratorsCompleted
-
PATHBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PT Bio Farma and other collaboratorsRecruiting
-
PATHBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PT Bio Farma and other collaboratorsRecruiting
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological... and other collaboratorsUnknown
-
Pauline VerdijkWorld Health OrganizationCompleted